Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect of chemotherapy and occurs in up to 90% of patients. There is no specific treatment to prevent or reverse the severe pain that can be caused by CIPN.
As CIPN is a dose-dependent side effect of chemotherapy, efforts to reduce the risk of developing CIPN are based on reducing chemotherapy dose, or increasing intervals between treatment sessions. However this may compromise cancer treatment outcomes. Current approaches are limited to symptomatic management, for example, in the management and reduction of dysesthesia and pain. Several potential neuroprotective agents, such as amifostine and vitamin E, have been studied, but none have attained clinical translation successfully.
Thus, an effective way to prevent CIPN, that does not diminish the anticancer effects of the chemotherapy drug, is highly desirable. Such an approach exists in the application of limb hypothermia to combat CIPN which has been shown in various studies to be an effective, non-invasive, non-drug therapeutic intervention to combat CIPN.
Under this funding, the team will refine and further test their augmented four-limb cooling device which comprises integrated cooling feedback control via wireless temperature monitoring, and compressive cooling wraps.
Principal Investigator: Professor Einar WILDER-SMITH
Institution: National University Health System
NHIC Ref: NHIC-I2D-1409031